Why Doesn't a Low-Glucose Alarm Wake Up a Heavy Sleeper?

A continuous glucose monitor’s “urgent low” alarm is built to be nearly impossible to miss. On a current iPhone, it can override Do Not Disturb entirely, one of a small number of consumer apps Apple grants that permission to. It still fails to wake a meaningful share of the people wearing it, and the reason has almost nothing to do with the sound itself. In a 2007 sleep-lab study out of the University of Lübeck in Germany, researchers lowered blood sugar to the same hypoglycemic level in sixteen adults with type 1 diabetes and sixteen healthy controls while they slept. Ten of the sixteen healthy sleepers woke up on their own. One of the sixteen people with diabetes did. The alarm’s job was never just to reach the pillow. It has to reach a body that the low blood sugar it’s warning about has already started to quiet down, which is a much harder target, and one the alarm has no way of accounting for.

The low itself dulls the response meant to catch it

The Lübeck study, led by Bernd Schultes with senior author Jan Born and published in PLoS Medicine, didn’t test any device at all. It tested biology. Both groups slept in a lab while researchers infused insulin to bring plasma glucose down to about 2.2 mmol/L, roughly 40 mg/dL, tracking brain activity by EEG the whole time. In the healthy group, that drop reliably produced a measurable arousal response: heart rate changes, a shift in brain wave pattern, and in most cases full waking. In the group with type 1 diabetes, the same drop, on the same equipment, in people matched for age, sex, and body weight, produced almost none of that. Most of them slept through it.

Clinicians have a name for this, separate from any alarm: hypoglycemia-associated autonomic failure. Repeated episodes of low blood sugar over years appear to blunt the release of counterregulatory hormones like epinephrine that would otherwise both raise glucose and startle the body awake. The more low blood sugar a person has experienced, in other words, the less their body reacts to the next one, at exactly the moment an external device is counting on that reaction to finish the job the hormones used to do alone. A CGM alarm isn’t just competing with normal sleep inertia. It’s trying to substitute for a hormonal alarm that hypoglycemia itself has already partly disabled in the population wearing the device.

What the alarm actually has to overcome

CGM makers have known this for years. It’s the entire reason the “urgent low” tier exists as a separate, more insistent alert from an ordinary low-glucose notification, and why manufacturers went to the trouble of getting Apple’s Critical Alerts entitlement in the first place, a permission Apple grants case by case and withholds from almost every other category of app. Getting that entitlement was a real engineering and regulatory achievement: it guarantees the sound plays through a muted, Do Not Disturb, or Focus-mode phone. What it doesn’t guarantee, and can’t, is that a brain in slow-wave sleep, its hypoglycemia response already dulled, will process that sound as something worth waking up for.

The sensor itself has no speaker. A Dexcom or Libre patch measures interstitial glucose and transmits the number over Bluetooth to a phone app or a dedicated palm-sized receiver, and it’s that second device, not the arm patch, that has to make noise, stay charged, and stay in range. Every one of those is a separate point where the chain can break before the physiology ever gets a chance to fail on its own.

Abbott’s Freestyle Libre took a slower path to even having this problem. The original Libre, sold in the US starting in 2017, required the wearer to actively scan the sensor with a phone or reader to see a number; it had no continuous background alarm at all. Real-time low and high alerts didn’t arrive until the Libre 2 generation, cleared by the FDA in 2020, several years into CGM being a mainstream part of diabetes care. For most of Libre’s early life in the US market, sleeping through a low wasn’t an arousal problem. There was simply no alarm yet to sleep through.

The recall that made the hardware failure literal

In May 2025, Dexcom issued an Urgent Medical Device Correction, later escalated by the FDA to a Class I recall, its most serious category, covering more than 700,000 G6, G7, ONE, and ONE+ receivers. A speaker defect meant some units could silently fail to sound an audible alert for a dangerously low or high reading while still showing the number on screen and still vibrating. Dexcom logged 56 reported injuries tied to the malfunction. The company’s fix was blunt and telling: it told users to test their receiver’s speaker manually every time they charged it, because there was no way for the device to verify its own alarm was working.

It’s a useful, if unwelcome, natural experiment. Even when every physiological problem this piece is about is set aside entirely, the alarm can still fail for a reason as mundane as a bad speaker component, and the person relying on it has no way to know until the night it doesn’t sound.

Loud isn’t the same as arousing

A separate line of research, unconnected to diabetes, helps explain why cranking the volume only goes so far. Orfeu Buxton, then at Harvard Medical School and Brigham and Women’s Hospital, led a 2012 study in Annals of Internal Medicine measuring how different hospital sounds affected sleeping patients. IV pump alarms and human voices woke roughly 70 to 90 percent of subjects at just 40 decibels, whisper-quiet in absolute terms. Other sounds, matched or exceeded in decibel level, produced far less arousal. Pitch, novelty, and pattern predicted waking better than raw loudness did.

Line that finding up against a phone’s physical ceiling: a smartphone speaker at maximum volume typically tops out somewhere in the 80s to low 90s of decibels measured close to the source, comfortably above the 40 dBA that woke most of Buxton’s subjects in light sleep. On paper, a CGM alarm should have plenty of headroom to work in most sleep stages. The gap opens in slow-wave sleep, where the auditory arousal threshold climbs sharply regardless of decibel level, and it opens further because a CGM alarm, unlike a random hospital sound, is heard on a loop, night after night, at the same pitch, in the same rhythm. The thalamus filters sound during sleep by pattern and personal relevance more than by volume, and a tone the brain has already classified, correctly on most nights, as a false alarm is a strong candidate for exactly the kind of signal that gating filters out. The device that’s supposed to interrupt sleep on the one night it matters is, by construction, using the same sound it used on the nine nights it didn’t.

What automated insulin delivery changed, and what it didn’t

The most effective fix device makers have found skips the alarm question altogether, at least for one category of user: removing the need to wake up in the first place. Predictive low-glucose suspend technology, and the hybrid closed-loop algorithms that followed it, like Tandem’s Control-IQ and Medtronic’s 780G, watch the glucose trend and automatically reduce or pause insulin delivery before a low develops, no alarm, no human response, needed to prevent it. For an insulin pump user on one of these, a large share of overnight lows that a decade ago would have depended on someone waking up now simply don’t happen.

That fix only reaches pump users, though, and most people who wear a CGM are not pump users. A large majority of people with type 1 diabetes worldwide, and nearly all CGM wearers with type 2 diabetes, manage insulin by injection, with no pump attached to the sensor and no algorithm able to act on a falling number automatically. For them, the alarm chain described above, sound, hardware, and a body hypoglycemia has already dulled, is still the entire safety net. Automated insulin delivery didn’t solve the CGM wake-up problem so much as make it optional for a subset of users wealthy enough, insured well enough, and willing enough to wear a pump.

What parents and patients actually do about it

Ask people who manage this every night and the answers rarely involve a single fix. They involve redundancy piled on top of an alarm nobody fully trusts on its own. A composite drawn from several accounts, not a real named individual, illustrates the shape of it: call her Colette, a parent of a nine-year-old with type 1 diabetes. Her son’s Dexcom shares readings to her phone through the Follow app, propped on her own nightstand rather than his, on the theory that a parent, dulled only by ordinary sleep and not by years of hypoglycemia, gives the alarm a better shot at working on at least one of the two phones in the house. She still sets a manual 2 a.m. check most nights, glucose trend or not, because Michelle Van Name and colleagues, in a multi-site study anchored at Yale School of Medicine and published in Pediatric Diabetes in 2018, found that fear of nighttime hypoglycemia, not daytime numbers, was the single largest driver of parental anxiety and lost sleep among parents of young children with type 1 diabetes. The redundancy comes from knowing, from the physiology described above, that the alarm will eventually fail on some night nobody can predict in advance.

Other households add a bed-shaker puck under the mattress tied to the phone’s alarm, since vibration reaches slow-wave sleep less reliably than sound but through a different pathway, which is worth having even at low added odds. Some keep the child’s door open and a hallway light on, cheap sensory backups that cost nothing if the primary alarm holds. None of it is framed, by the people doing it, as distrust of the device. It’s closer to what a seven-step escalation guide for waking a heavy sleeper already argues on unrelated ground: a single channel, however well engineered, rarely beats several weaker ones aimed at different arousal pathways at once. Repeated exposure to alarms that turn out to be false also has its own name in the sleep and safety literature, alarm fatigue, and a CGM that fires several times a week for glucose swings that resolve on their own is, without meaning to, training the exact desensitization that makes the one urgent night harder to catch.

Continuous glucose monitors have still measurably reduced severe hypoglycemia at the population level compared with fingerstick testing alone, and nothing here argues otherwise. The distinction is which part of the problem a louder, more permission-heavy alarm can actually solve. Getting the sound to the pillow, reliably, at any hour, past Do Not Disturb, was the achievable engineering problem, and manufacturers largely solved it. Getting a body that hypoglycemia has already made harder to rouse to respond to that sound was never an engineering problem in the first place.